Ion News and Research

RSS

Scientists use specialized fluorescent protein to study nerve cell activity

Electrical currents are invisible to the naked eye - at least they are when they flow through metal cables. In nerve cells, however, scientists are able to make electrical signals visible. Working with fellow experts from Switzerland and Japan, scientists from the Max Planck Institute for Medical Research in Heidelberg successfully used a specialized fluorescent protein to visualize electrical activity in neurons of living mice.

6 May 2010

Medication used to treat heart arrhythmias also reduces myotonic dystrophy: Researchers

A medication most often used to treat heart arrhythmias also reduces a central symptom of myotonic dystrophy, the most common type of muscular dystrophy in adults.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

The Netherlands Organisation for Scientific Research (NWO) has awarded 31 grants in the Investment Subsidy NWO Medium programme for the acquisition of equipment, the setting up of data collections and the production of software and bibliographies. The total investment amounts to 10 million euro.

30 Apr 2010

Boston-Power announces lithium-ion battery technology for medical device and equipment market

Boston-Power®, Inc., the rapidly growing provider of next-generation lithium-ion batteries, is responding to strong customer and partner demand by bringing its industry-leading lithium-ion battery technology to the multi-billion dollar global medical device and equipment market. Boston-Power's lithium-ion battery cells deliver unmatched levels of long life, fast charge and safety to a market that demands the most stringent standards of battery reliability to ensure that patients receive the highest quality of care.

28 Apr 2010

Temperature-sensing ability in proteins remain a mystery

Scientists at The Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation (GNF) have shed new light on the molecular mechanism that enables us to sense temperature, such as the heat from a sizzling stove. In addition to contributing to our knowledge of basic biology, the findings could one day lead to new therapies for conditions such as acute or chronic inflammatory pain.

24 Apr 2010

New understanding of nerve cell influence in exchange of information

Nerve cells communicate with each other by means of electrical impulses. To create such an impulse, the cells exchange charged ions with their environment. However, the role played by the ever-present chloride channels remained obscure, although some theories predicted a relation between the chloride channel ClC-2 and epilepsy.

24 Apr 2010

As hip replacement steadily increasing, patients need to know the facts before procedure: Surgeons

On the golf course, in the garden, or at the shopping mall, most people want to stay active, regardless of age. As the number of Americans reaching their 60s grows daily, the demand for mobility-restoring procedures, such as hip replacement, is steadily increasing.

24 Apr 2010

Sonic Innovations wins Best in Show award at AudiologyNOW! conference

Sonic Innovations, Inc. received a Best in Show award based on attendees' votes at the AudiologyNOW! conference for its tradeshow booth. The conference was held April 14 through 17 in San Diego, California and was attended by nearly 7,000 hearing care professionals.

21 Apr 2010

Researchers identify potential drug target for treatment of Alzheimer's disease

Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells.

21 Apr 2010

First case of treating cystic fibrosis and Crohn's disease with infliximab

Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves an anomalous function of the exocrine glands, caused by a mutation of a gene (cystic fibrosis transmembrane conductance regulator, CFTR) located on chromosome 7, which codes for a protein involved in ion transport through the cell membrane.

20 Apr 2010

Breathe California names CODA Automotive as winner of Clean Air Award

CODA Automotive, a California-based electric car and battery company, was named a Clean Air Award winner in the technology development category by Breathe California. The award, presented today in San Francisco, highlights standout efforts to combat climate change and air pollution in the business, government, education and non-profit sectors.

17 Apr 2010

Researchers discover link between protein structure and hearing process

Rising from the top surface of each of the specialized receptor cells in our inner ears is a bundle of sensory cilia that responds to the movement of sound. As sensitive as they are fragile, these cilia can move to wisps of sound no larger than a molecule-but can shear at sounds that are larger than life.

17 Apr 2010

New research identifies cellular channel that regulates skin and hair growth

Skin and hair follicles are constantly renewed in the body, maintained by specialized stem cells. New research from Children's Hospital Boston identifies a small cellular channel that regulates skin and hair growth and that could be targeted with small-molecule drugs, potentially treating variety of skin conditions, as well as thinning hair or unwanted hair growth. Findings appear in the April 16, 2010 issue of Cell.

16 Apr 2010

IBA's PBS system for Proton Therapy granted CE Mark

IBA's second generation Pencil Beam Scanning system for Proton Therapy, which further enhances the performance of anti-cancer proton treatments, has been granted the CE Mark, certifying that the product has met European Union medical device regulations.

16 Apr 2010

Thermo Fisher Scientific acquires Proxeon

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that it has acquired Proxeon A/S, an innovative supplier of products for proteomics analysis headquartered in Odense, Denmark.

From Thermo Fisher Scientific Inc. 16 Apr 2010

High sensitivity of Zetasizer Nano proves essential for protein aggregation studies

Dr Martin Muschol, Assistant Professor at the University of South Florida’s (USF) Department of Physics and his team are carrying out important research to gain a better understanding of protein aggregation phenomena, including protein crystallization and amyloid fibril growth. Using the Zetasizer Nano ZS, from Malvern Panalytical (Malvern Panalytical, UK), the USF researchers have been able to perform temperature controlled static and dynamic light scattering (DLS) measurements of protein hydration, protein interactions and aggregation kinetics in vitro.

From Malvern Panalytical 15 Apr 2010

Sonic Innovations to unveil new 12-channel BTE hearing aid at AudiologyNOW! conference

Sonic Innovations, Inc. will unveil its new 12-channel super power behind-the-ear (BTE) hearing aid, Endura, at the AudiologyNOW! conference in San Diego, California, April 14 through 17. Endura provides exceptional amplification for those suffering from severe-to-profound hearing loss.

15 Apr 2010

Use of silver dressing in burn cases questioned

The use of expensive silver dressing in burn cases is being brought under the scanner by an editorial in the Drug and Therapeutics Bulletin. The NHS has increased its spending from £23 million in 2005 to around £25 million in 2006/7 on such products. The author asks if expensive silver dressing is really justified when cheaper alternatives are available.

15 Apr 2010

Researchers invent zinc-stapled insulin to reduce insulin-related cancer risk

For millions of Americans with Type-2 diabetes and inject insulin to control diabetes (with onset typically in adulthood) the associated risk of cancer is of increasing concern. Studies have demonstrated that obesity and excess insulin - whether naturally produced by the body or injected in synthetic form - are associated with an increased incidence of some common cancers.

13 Apr 2010